Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Entero Healthcare Solutions Limited ( (IN:ENTERO) ) has shared an update.
Entero Healthcare Solutions Limited has disclosed that the Senior Drugs Control Officer cum Licensing Authority, Karnal Zone, has temporarily suspended the drug licenses of its wholly owned subsidiary, Atreja Healthcare Solutions Private Limited, for three days from January 30 to February 1, 2026, due to contraventions of the Drugs and Cosmetics Act, 1940 and related rules in the conduct of Atreja’s business. The company stated that the suspension is an administrative action with no material impact on Entero’s overall financials, operations, or other activities as a listed entity, though it anticipates a potential revenue loss of about Rs 1.88 million from the brief suspension, signaling limited operational and financial implications for stakeholders.
More about Entero Healthcare Solutions Limited
Entero Healthcare Solutions Limited operates in the healthcare sector, with activities that include pharmaceutical distribution through subsidiaries such as Atreja Healthcare Solutions Private Limited. The company serves the Indian market and is listed on both the BSE and NSE, indicating a focus on regulated, large-scale participation in the country’s healthcare supply chain.
Average Trading Volume: 45,499
Technical Sentiment Signal: Sell
Current Market Cap: 50.43B INR
Find detailed analytics on ENTERO stock on TipRanks’ Stock Analysis page.